179 related articles for article (PubMed ID: 21901297)
21. Conversion ratios for opioid switching: a pragmatic study.
Mercadante S; Adile C; Ferrera P; Grassi Y; Cascio AL; Casuccio A
Support Care Cancer; 2022 Dec; 31(1):91. PubMed ID: 36580152
[TBL] [Abstract][Full Text] [Related]
22. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial.
Riley J; Branford R; Droney J; Gretton S; Sato H; Kennett A; Oyebode C; Thick M; Wells A; Williams J; Welsh K; Ross J
J Pain Symptom Manage; 2015 Feb; 49(2):161-72. PubMed ID: 24975432
[TBL] [Abstract][Full Text] [Related]
23. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
24. Outcome of opioid switching 4 weeks after discharge from a palliative care unit.
Mercadante S; Ferrera P; Casuccio A
Curr Med Res Opin; 2011 Dec; 27(12):2357-60. PubMed ID: 22029619
[TBL] [Abstract][Full Text] [Related]
25. Opioid plasma concentration during switching from morphine to methadone: preliminary data.
Mercadante S; Bianchi M; Villari P; Ferrera P; Casuccio A; Fulfaro F; Gebbia V
Support Care Cancer; 2003 May; 11(5):326-31. PubMed ID: 12690541
[TBL] [Abstract][Full Text] [Related]
26. High doses of oxycodone-naloxone combination may provide poor analgesia.
Mercadante S; Ferrera P; Adile C
Support Care Cancer; 2011 Sep; 19(9):1471-2. PubMed ID: 21656338
[TBL] [Abstract][Full Text] [Related]
27. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Ripamonti C; Groff L; Brunelli C; Polastri D; Stavrakis A; De Conno F
J Clin Oncol; 1998 Oct; 16(10):3216-21. PubMed ID: 9779694
[TBL] [Abstract][Full Text] [Related]
28. Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
Mercadante S; Casuccio A; Calderone L
J Clin Oncol; 1999 Oct; 17(10):3307-12. PubMed ID: 10506634
[TBL] [Abstract][Full Text] [Related]
29. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.
Riley J; Ross JR; Rutter D; Wells AU; Goller K; du Bois R; Welsh K
Support Care Cancer; 2006 Jan; 14(1):56-64. PubMed ID: 15952009
[TBL] [Abstract][Full Text] [Related]
30. Changes of QTc interval after opioid switching to oral methadone.
Mercadante S; Prestia G; Adile C; Casuccio A
Support Care Cancer; 2013 Dec; 21(12):3421-4. PubMed ID: 23949740
[TBL] [Abstract][Full Text] [Related]
31. Opioid substitution to reduce adverse effects in cancer pain management.
Ashby MA; Martin P; Jackson KA
Med J Aust; 1999 Jan; 170(2):68-71. PubMed ID: 10026686
[TBL] [Abstract][Full Text] [Related]
32. Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.
Peirano GP; Mammana GP; Bertolino MS; Pastrana T; Vega GF; Russo J; Varela G; Vignaroli E; Ruggiero R; Armesto A; Camerano G; Dran G
Support Care Cancer; 2016 Aug; 24(8):3551-6. PubMed ID: 27022964
[TBL] [Abstract][Full Text] [Related]
33. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Santiago-Palma J; Khojainova N; Kornick C; Fischberg DJ; Primavera LH; Payne R; Manfredi P
Cancer; 2001 Oct; 92(7):1919-25. PubMed ID: 11745266
[TBL] [Abstract][Full Text] [Related]
34. Oxycodone for cancer-related pain.
Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
Cochrane Database Syst Rev; 2015 Feb; (2):CD003870. PubMed ID: 25723351
[TBL] [Abstract][Full Text] [Related]
35. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
[TBL] [Abstract][Full Text] [Related]
36. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
37. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
38. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.
Ripamonti C; De Conno F; Groff L; Belzile M; Pereira J; Hanson J; Bruera E
Ann Oncol; 1998 Jan; 9(1):79-83. PubMed ID: 9541687
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
Roland CL; Setnik B; Cleveland JM; Brown DA
Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
[TBL] [Abstract][Full Text] [Related]
40. Oxycodone and a useful book.
Enck RE
Am J Hosp Palliat Care; 2011 Jun; 28(4):217-8. PubMed ID: 21622488
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
